Database : MEDLINE
Search on : Vulvar and Diseases [Words]
References found : 4133 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 414 go to page                         

  1 / 4133 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29327306
[Au] Autor:Hintze JM; O'Neill JP
[Ad] Address:Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin, Ireland. hintzej@tcd.ie.
[Ti] Title:Strengthening the case for gender-neutral and the nonavalent HPV vaccine.
[So] Source:Eur Arch Otorhinolaryngol;275(4):857-865, 2018 Apr.
[Is] ISSN:1434-4726
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:PURPOSE: The purpose of this review is to highlight the benefits of gender-neutral and the nonavalent human papillomavirus vaccination. Human papillomavirus infection is the most commonly sexually transmitted disease and is known to cause several types of cancers, including cervical, vulvar, vaginal, penile, oropharyngeal, anal, and rectal. 5% of cancers every year are attributable to human papillomavirus infection, with cervical cancer the most common and oropharyngeal cancer estimated to surpass the incidence of cervical cancer by 2020. METHODS: PubMed and MEDLINE were searched using the following search terms: [(human papillomavirus OR HPV) AND (vaccine OR vaccination)] AND [(gardasil OR gardasil9 OR cervarix OR quadrivalent OR nonavalent OR ninevalent) OR (gender neutral OR male)]. RESULTS: There are currently three different types of human papillomavirus vaccinations and range in cover from four to nine different strains known to cause human disease. Most countries currently only supply vaccination to females; however, recent data point towards both a personal benefit as well as a cost-effective population-based benefit with gender-neutral vaccination. Data from female vaccination only have shown the vaccine to be effective in preventing premalignant cervical lesions, and are believed to have the same effect for other human papillomavirus cancers. Male vaccination not only provides personal benefit but also has a "herd effect" for females by preventing the propagation of the virus. CONCLUSION: Gender-neutral vaccination provides significant cost-effective benefits for preventing human papillomavirus-related diseases, and this effect is further enhanced by the use of the nonavalent vaccine.
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1801
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.1007/s00405-018-4866-y

  2 / 4133 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29419702
[Au] Autor:Baradwan S; Wadi KA
[Ti] Title:Unilateral ectopic breast tissue on vulva in postpartum woman: A case report.
[So] Source:Medicine (Baltimore);97(6):e9887, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Ectopic mammary gland tissues occur in about 2% to 6% of women in general population. Vulva is considered a rare site for the ectopic breast tissue. PATIENT CONCERNS: We report a rare case of a 27 year-old woman, para 2 and presenting as a vulvar mass in the postpartum period. DIAGNOSES: Ectopic mammary tissue in vulva. INTERVENTIONS: The mass was removed by wide local excision. Histopathological assessment revealed features of ectopic mammary tissue CONCLUSION:: The vulvar region is one of the reported sites for ectopic breast tissue in the body. The presence of a rapidly enlarging, well-encapsulated mass in the vulvar region associated with recent delivery or lactation is suggestive of ectopic breast tissue. LESSONS: It is important for clinicians to get a good history and consider ectopic breast tissue on vulva in postpartum women and confirm diagnosis via biopsy with histopathological examination.
[Mh] MeSH terms primary: Breast
Choristoma
Dissection/methods
Vulvar Diseases
[Mh] MeSH terms secundary: Adult
Biopsy/methods
Choristoma/diagnosis
Choristoma/pathology
Choristoma/surgery
Diagnosis, Differential
Female
Humans
Postpartum Period
Treatment Outcome
Vulvar Diseases/diagnosis
Vulvar Diseases/pathology
Vulvar Diseases/surgery
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180214
[Lr] Last revision date:180214
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180209
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009887

  3 / 4133 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28470128
[Au] Autor:Parsons BF; Ryder N
[Ad] Address:1 Pacific Clinic Newcastle, HNE Sexual Health, Newcastle, NSW, Australia.
[Ti] Title:Pseudoepitheliomatous hyperplasia causing a painful plaque in a HIV-infected female.
[So] Source:Int J STD AIDS;28(7):723-725, 2017 06.
[Is] ISSN:1758-1052
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Dermatological conditions are more common and can present atypically, in human immunodeficiency virus-infected individuals. This case report describes a 22-year-old human immunodeficiency virus-positive Caucasian female who presented with a vulval lesion eight weeks after starting antiretroviral treatment. Clinical examination revealed a 2 cm well-demarcated plaque on the outer aspect of the left labium minus. The lesion was tender, no contact bleeding or ulceration present. She was presumptively treated for chancroid and herpes simplex with 500 mg ceftriaxone IM stat, 1 g azithromycin PO stat, and valacyclovir 500 mg BD for five days. The lesion persisted despite treatment, and during follow-up, a punch biopsy was carried out. She was diagnosed with pseudoepitheliomatous hyperplasia of the epidermis. In addition to highlighting this condition that has been previously reported in human immunodeficiency virus/herpes simplex virus co-infection, this case demonstrates that unusual skin presentations must be considered in human immunodeficiency virus-infected individuals and illustrates the importance of biopsy for any non-healing lesions.
[Mh] MeSH terms primary: HIV Infections/complications
Herpes Genitalis/diagnosis
Hyperplasia/pathology
Vulva/pathology
Vulvar Diseases/diagnosis
[Mh] MeSH terms secundary: Adult
Anti-HIV Agents/therapeutic use
Biopsy
Coinfection/virology
Female
HIV Infections/drug therapy
Herpes Genitalis/complications
Herpes Genitalis/drug therapy
Herpes Genitalis/microbiology
Humans
Immunocompromised Host
Simplexvirus
Treatment Outcome
Vulvar Diseases/complications
Vulvar Diseases/drug therapy
Vulvar Diseases/microbiology
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Anti-HIV Agents)
[Em] Entry month:1712
[Cu] Class update date: 180205
[Lr] Last revision date:180205
[Js] Journal subset:IM; X
[Da] Date of entry for processing:170505
[St] Status:MEDLINE
[do] DOI:10.1177/0956462416676020

  4 / 4133 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29339071
[Au] Autor:Ren L; Zhao Y; Huo X; Wu X
[Ad] Address:Department of Gynecology and Obstetrics, The First Affiliated Hospital of China Medical University, Liaoning 110001, China.
[Ti] Title:MiR-155-5p promotes fibroblast cell proliferation and inhibits FOXO signaling pathway in vulvar lichen sclerosis by targeting FOXO3 and CDKN1B.
[So] Source:Gene;, 2018 Jan 12.
[Is] ISSN:1879-0038
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Vulvar lichen sclerosis (VLS) is a chronic inflammatory skin disorder. Evidence is accumulating that microRNAs (miRNAs) exert crucial roles in initiation and development of a wide range of human diseases. MiR-155-5p has been frequently reported to be implicated in the tumorigenesis and progression of multiple types of cancers, however, its biological role in VLS remains unclear. This study aimed to explore the role of miR-155-5p in VLS and clarify the potential molecular mechanisms involved. In the present study, miR-155-5p was observed to be significantly upregulated in VLS tissues. Functional studies showed that miR-155-5p facilitated cell proliferation, accelerated cell cycle progression and inhibited forkhead box O (FOXO) signaling pathway in fibroblast cells. Mechanical studies demonstrated that miR-155-5p exerted its promoting effects on fibroblast cell proliferation via targeting both forkhead box O3 (FOXO3) and cyclin-dependent kinase inhibitor 1B (CDKN1B). Besides, Pearson's correlation analysis revealed that miR-155-5p expression was negatively correlated with the mRNA expression of FOXO3 and CDKN1B in VLS tissues. Taken together, our results indicate that miR-155-5p promotes fibroblast cell proliferation and inhibits FOXO signaling pathway by negative modulation of both FOXO3 and CDKN1B in VLS, and that miR-155-5p may be used to be a potential therapeutic target for VLS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180117
[Lr] Last revision date:180117
[St] Status:Publisher

  5 / 4133 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
SciELO Brazil full text

[PMID]: 29267481
[Au] Autor:Damiani L; Quadros M; Posser V; Minotto R; Boff AL
[Ad] Address:Dermatology Service of Santa Casa de Misericórdia Porto Alegre - Porto Alegre (RS), Brazil.
[Ti] Title:Zoon vulvitis.
[So] Source:An Bras Dermatol;92(5 Suppl 1):166-168, 2017.
[Is] ISSN:1806-4841
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:Zoon vulvitis or vulvitis chronica plasmacellularis is a rare, chronic benign inflammation of the vulvar mucosa, diagnosed histologically, with variable therapeutic responses. It is important to be diagnosed because it mimics the presentation of other genital conditions, such as lichen planus and squamous cell carcinoma, which require specific treatment. We report a case of a female patient with three asymptomatic shallow ulcers on the labia minora. Laboratory tests ruled out infectious diseases and the biopsy was consistent with Zoon Vulvitis.
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1712
[Cu] Class update date: 171224
[Lr] Last revision date:171224
[St] Status:In-Process

  6 / 4133 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29178840
[Au] Autor:Rantshabeng PS; Moyo S; Moraka NO; Ndlovu A; MacLeod IJ; Gaseitsiwe S; Kasvosve I
[Ad] Address:Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Private Bag UB072, 4775 Notwane Rd., Gaborone, Botswana. trishrant@gmail.com.
[Ti] Title:Prevalence of oncogenic human papillomavirus genotypes in patients diagnosed with anogenital malignancies in Botswana.
[So] Source:BMC Infect Dis;17(1):731, 2017 Nov 25.
[Is] ISSN:1471-2334
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Human papillomavirus (HPV) associated malignancies are the leading cause of cancer death in Botswana. We sought to determine causative HPV types in patients with anogenital malignancies in Botswana to inform vaccine strategy. METHODS: We used formalin-fixed and paraffin-embedded (FFPE) tissue blocks from patients diagnosed with anal, penile and vulvar squamous cell carcinomas between the years, 2014 and 2016. Presence of HPV 16, 18, or other high-risk (HR) types was detected using Abbott m2000 real-time PCR platform. Tissues with other high-risk types were subsequently analysed using a multiplex qPCR assay that includes 15 validated fluorophore probes. RESULTS: A total of 126 tissue specimens, comprising of 21 anal (9 males, 12 females), 31 penile and 74 vulvar were studied. Ninety-three (73.8%) patients had their HIV status documented in the records while the rest did not. Eighty-three (83) out of 93 were HIV positive, a prevalence of 89.4% (95% CI: 81-94). HPV was detected in 68/126 (54%) tissues, of which 69% (95% CI: 54-79) had HPV 16 only, 28% (95% CI: 19-40) had other hr.-HPV types and 2.9% (95% CI, 3.5-10.1) were co-infected with HPV 16 and other hr.-types. Other high-risk types detected included HPV 26, 31, 33, 35, 39, 45, 51, 52, 66 and 68. HPV 18 was not detected. Multiple-type HPV infection was detected in 44 of 47 (93.6%) HIV positive participants co-infected with HPV. In HIV-negative individuals, only HPV 16 was detected. CONCLUSION: In our study, anogenital carcinomas were associated with HPV 16 and other hr.-HPV types besides HPV 16 and 18. HIV co-infected patients had multiple hr.-HPV types detected whereas in HIV-negative patients only HPV 16 was detected. Our study suggests that multivalent vaccines may be more suitable in this setting, especially for HIV-infected individuals.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171219
[Lr] Last revision date:171219
[St] Status:In-Process
[do] DOI:10.1186/s12879-017-2832-8

  7 / 4133 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29202940
[Au] Autor:Faubion SS; Sood R; Kapoor E
[Ad] Address:Women's Health Clinic, Division of General Internal Medicine, Mayo Clinic, Rochester, MN. Electronic address: faubion.stephanie@mayo.edu.
[Ti] Title:Genitourinary Syndrome of Menopause: Management Strategies for the Clinician.
[So] Source:Mayo Clin Proc;92(12):1842-1849, 2017 Dec.
[Is] ISSN:1942-5546
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Genitourinary syndrome of menopause (GSM), previously known as atrophic vaginitis or vulvovaginal atrophy, affects more than half of postmenopausal women. Caused by low estrogen levels after menopause, it results in bothersome symptoms, including vaginal dryness, itching, dyspareunia, urinary urgency and increased frequency, and urinary tract infections. Even though women with GSM can have sexual dysfunction that interferes with partner relationships, women are often embarrassed to seek treatment, and health care professionals do not always actively screen for GSM. As a result, GSM remains underdiagnosed and undertreated. Several effective treatments exist, but low-dose vaginal estrogen therapy is the criterion standard. It is effective and safe for most patients, but caution is suggested for survivors of hormone-sensitive cancers. Newer treatment options include selective estrogen receptor modulators, vaginal dehydroepiandrosterone, and laser therapy. Nonprescription treatments include vaginal lubricants, moisturizers, and dilators. Pelvic floor physical therapy may be indicated for some women with concomitant pelvic floor muscle dysfunction. Sex therapy may be helpful for women with sexual dysfunction. This concise review presents a practical approach to the evaluation and management of GSM for the primary care physician.
[Mh] MeSH terms primary: Atrophic Vaginitis/therapy
Menopause
Urinary Incontinence/therapy
Vaginal Diseases/therapy
Vulvar Diseases/therapy
Women´s Health
[Mh] MeSH terms secundary: Estrogen Replacement Therapy
Female
Humans
Middle Aged
Quality of Life
Syndrome
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Em] Entry month:1712
[Cu] Class update date: 171212
[Lr] Last revision date:171212
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171206
[St] Status:MEDLINE

  8 / 4133 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29159773
[Au] Autor:Saito T; Tabata T; Ikushima H; Yanai H; Tashiro H; Niikura H; Minaguchi T; Muramatsu T; Baba T; Yamagami W; Ariyoshi K; Ushijima K; Mikami M; Nagase S; Kaneuchi M; Yaegashi N; Udagawa Y; Katabuchi H
[Ad] Address:Gynecology Service, National Kyushu Cancer Center, Fukuoka, Japan.
[Ti] Title:Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.
[So] Source:Int J Clin Oncol;, 2017 Nov 20.
[Is] ISSN:1437-7772
[Cp] Country of publication:Japan
[La] Language:eng
[Ab] Abstract:BACKGROUND: Vulvar cancer and vaginal cancer are relatively rare tumors, and there had been no established treatment principles or guidelines to treat these rare tumors in Japan. The first version of the Japan Society of Gynecologic Oncology (JSGO) guidelines for the treatment of vulvar cancer and vaginal cancer was published in 2015 in Japanese. OBJECTIVE: The JSGO committee decided to publish the English version of the JSGO guidelines worldwide, and hope it will be a useful guide to physicians in a similar situation as in Japan. METHODS: The guideline was created according to the basic principles in creating the guidelines of JSGO. RESULTS: The guidelines consist of five chapters and five algorithms. Prior to the first chapter, basic items are described including staging classification and history, classification of histology, and definition of the methods of surgery, radiation, and chemotherapy to give the reader a better understanding of the contents of the guidelines for these rare tumors. The first chapter gives an overview of the guidelines, including the basic policy of the guidelines. The second chapter discusses vulvar cancer, the third chapter discusses vaginal cancer, and the fourth chapter discusses vulvar Paget's disease and malignant melanoma. Each chapter includes clinical questions, recommendations, backgrounds, objectives, explanations, and references. The fifth chapter provides supplemental data for the drugs that are mentioned in the explanation of clinical questions. CONCLUSION: Overall, the objective of these guidelines is to clearly delineate the standard of care for vulvar and vaginal cancer with the goal of ensuring a high standard of care for all women diagnosed with these rare diseases.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171121
[Lr] Last revision date:171121
[St] Status:Publisher
[do] DOI:10.1007/s10147-017-1193-z

  9 / 4133 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29104417
[Au] Autor:Schild-Suhren M; Soliman AA; Malik E
[Ad] Address:Universitätsklinik für Gynäkologie und Geburtshilfe, Klinikum Oldenburg AöR, Fakultät für Medizin und Gesundheitswissenschaften, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany.
[Ti] Title:Pubic Hair Shaving Is Correlated to Vulvar Dysplasia and Inflammation: A Case-Control Study.
[So] Source:Infect Dis Obstet Gynecol;2017:9350307, 2017.
[Is] ISSN:1098-0997
[Cp] Country of publication:Egypt
[La] Language:eng
[Ab] Abstract:Objective: The risk factors for vulvar dysplasia and infections are not fully known. In this study, we aimed to investigate the correlation between pubic hair shaving and the occurrence of vulvar inflammation, dysplasia, and cancer. Methods: This study was performed between January 2013 and December 2016 in which a standardized questionnaire concerning genital hair shaving was administered to vulvar dysplasia and cancer patients and healthy participants. The presence of human papilloma virus (HPV) infection and the occurrence of genital inflammation were documented. Results: We recruited 49 patients with vulvar dysplasia or cancer and 234 healthy women as a control group. Smoking, HPV infection, genital inflammation, and complete pubic hair removal were significantly more common in the vulvar dysplasia/cancer group. Pubic hair shaving per se presented a clear association with vulvar dysplasia/cancer. Shaving the labia majora in particular showed also an association. Conclusion: Our findings suggest that partial or complete pubic hair shaving using a razor is correlated with and could be a potential risk factor for the development of genital inflammation, vulvar dysplasia, and malignancies. These results need to be confirmed in larger studies. HPV status and genital inflammation should be documented by medical personnel.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1711
[Cu] Class update date: 171108
[Lr] Last revision date:171108
[St] Status:In-Process
[do] DOI:10.1155/2017/9350307

  10 / 4133 MEDLINE  
              first record previous record
select
to print
Photocopy
SciELO Brazil full text

[PMID]: 28954114
[Au] Autor:Shi G; Li W; Liang N; Wang TT; Zhou Y; Fan YM
[Ad] Address:Department of Dermatology, Affiliated Hospital of Guangdong Medical University - Guangdong Province, China.
[Ti] Title:Multiple vulvar dilated pores in a postmenopausal woman.
[So] Source:An Bras Dermatol;92(4):562-564, 2017 Jul-Aug.
[Is] ISSN:1806-4841
[Cp] Country of publication:Brazil
[La] Language:eng
[Ab] Abstract:Winer's dilated pore is an infrequent appendageal tumor characterized by a giant comedone on the face, neck, and upper trunk in adults. We report a 57-year-old woman who developed multiple asymptomatic black papules on both labia majora. Histopathology showed grouped dilated follicles lined by keratinizing squamous epithelium in the superficial dermis. The superficial lining epithelium and interfollicular epidermis were atrophic, while the deep epithelium showed mild proliferation and melanin pigmentation with a few short projections extending into the surrounding dermis. We diagnosed multiple Winer's dilated pores based on late-onset lesions and pathological features. This patient may represent the first case of multiple vulvar Winer's dilated pores. We suggest that electrocautery may be effective for treating this type of superficial entity.
[Mh] MeSH terms primary: Hair Follicle/pathology
Nevus/pathology
Skin Neoplasms/diagnosis
Vulvar Neoplasms/diagnosis
[Mh] MeSH terms secundary: Cysts/pathology
Diagnosis, Differential
Female
Hair Diseases/diagnosis
Humans
Middle Aged
Postmenopause
Skin Neoplasms/pathology
Vulvar Neoplasms/pathology
[Pt] Publication type:CASE REPORTS
[Em] Entry month:1710
[Cu] Class update date: 171010
[Lr] Last revision date:171010
[Js] Journal subset:IM
[Da] Date of entry for processing:170928
[St] Status:MEDLINE


page 1 of 414 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information